Today, on 24th 2025, Syngene Share Price experienced a significant decline of 10%. Analysts and market experts say that the company’s cautious outlook for the upcoming fiscal year (FY26) was the primary cause of this drop. Syngene’s profit margins may be under pressure as analysts expect the number of upcoming commercial deals may be fewer than expected.
Syngene Share Price in Today’s Market
Today, Syngene’s shares opened to the market at Rs. 691.00, a notable drop from the last session’s close of Rs. 749.15. At 10:10 a.m., Syngene’s share price was Rs. 675.60, nearly 9.82% lower than its previous close. According to the reports and estimates on Money Control, the current market capitalisation shows 27,195 cores; the UC Limit is 786.60, and the LC Limit is 636.75.
Q4 Financials
Despite revenue declining by 8% to Rs. 917 crore from last year, Syngene International posted a net profit of Rs. 189 crore in Q4 FY25, a 6% year-on-year increase. The EBITDA margin improved to 36% from 33% in Q4 FY24, while the EBITDA stood at Rs. 333 crore, a 1% decline.
Decreased demand for research and development services in the US biotech sector, impacted by a challenging funding environment, was the main cause of the revenue decline.
Recent News About Syngene
- Jonathan Hunt resigned as Syngene’s CEO in early February and was replaced by Peter Bains.
- This shift in leadership is a component of Syngene’s strategy to deal with the changing contract research and manufacturing market.
- For $36.5 million, Syngene purchased Emergent Manufacturing Operations, Baltimore’s first biologics factory in the United States, in March 2025.
- This facility in Baltimore-Bayview may open in the second half of 2025.
Syngene Share Price Target
According to the latest reports, Syngene International Ltd. has an average target of 1030. The consensus estimate represents an upside of 51.94% from the last price of 677.90.
Should You Buy, Sell, Or Hold?
Most analysts on Trendlyne recommend buying the shares. On MoneyControl, 40% of experts suggest buying, 10% support selling, and another 10% say hold. Before investing in Syngene, consider its long-term performance and consult your analyst to make the perfect move.
